Social media

Join ICON at ISPOR Europe 2025 – Booth 824! From health economics and outcomes research (HEOR) to real-world evidence and market access, ICON partners with you to deliver patient-centred solutions that drive value and a...

Join ICON at ISPOR Europe 2025 – Booth 824! From health economics and outcomes research (HEOR) to real-world evidence and market access, ICON partners with you to deliver patient-centred solutions that drive value and a...

A survey of obesity developers suggested many multi-indication assets are being developed with trial designs intended for single-indications. Are your development strategies adapted to a multi-indication landscape? Find ...

Sponsors of multi-indication therapies often face the challenge of reconciling regulatory mandates with clinically meaningful outcomes. ICON’s Simon Bruce and Jack Martin discuss trial design considerations for drugs wit...

In this new blog series, we review ISO 14971 (Application of risk management to medical devices) - its history, the principles embedded within it and how it relates to other standards and regulation. For the first editio...

In this new blog series, we review ISO 14971 (Application of risk management to medical devices) - its history, the principles embedded within it and how it relates to other standards and regulation. For the first editio...

Patient voices matter more than ever in obesity research. Are your trials designed to meet today’s expectations? Discover how to integrate COAs + DHTs effectively in this on-demand webinar led by our experts. https://o...

Patient voices matter more than ever in obesity research. Are your trials designed to meet today’s expectations? Discover how to integrate COAs + DHTs effectively in this on-demand webinar led by our experts. https://o...

Why do stability studies matter in early drug development? From shelf-life determination to regulatory readiness, a well-designed stability program ensures your drug product remains safe, effective, and reliable. Learn...

Why do stability studies matter in early drug development? From shelf-life determination to regulatory readiness, a well-designed stability program ensures your drug product remains safe, effective, and reliable. Learn...

At ICON, we combine therapeutic expertise, methodological rigor, and tailored intelligence to deliver SLRs that support regulatory milestones, clinical development, and market access. Discover how our integrated approac...

In 2024, we launched our Sustainable Procurement Policy and implemented sustainability engagement plans with key suppliers. Helping our ICON Cares Sustainable Procurement Program to advance our commitment to responsib...